Personalized medicine aims to tailor treatments to individual patients. Until now, this has been done using a small number of parameters to predict the course of a disease.

THURSDAY, Jan. 30, 2025 (HealthDay News) -- The absolute risk for thyroid cancer is low among patients receiving ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

Talimogene laherparepvec (T-VEC) demonstrates efficacy in cutaneous BCC, enhancing resectability and altering immune cell ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...